• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
BLT
Click for more information
5.77% 5.5¢

BENITEC BIOPHARMA LIMITED - Announcements

Currently unlisted. watchlist Created with Sketch. Add to my watchlist

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
BLTShare Trading Policy14/12/10
BLTCorrection to Appendix 3B13/12/10
BLTBenitec granted another RNA Interference Patent in EuropePRICE SENSITIVE13/12/10
BLTAppendix 3B Exercise of Options06/12/10
BLTAppendix 3B Partial Conversion01/12/10
BLTResults of Meeting29/11/10
BLTChairman Address To AGM26/11/10
BLTBenitec Key Patent - Notice of Intent to Re-Issue in the USAPRICE SENSITIVE08/11/10
BLTBenitec UK Patent UpdatePRICE SENSITIVE05/11/10
BLTCleansing Notice04/11/10
BLTBenitec Cash Flow Update29/10/10
BLTAppendix 4C - quarterlyPRICE SENSITIVE28/10/10
BLTAppendix 3B Partial Conversion27/10/10
BLTAnnual Report 201027/10/10
BLTNotice of Annual General Meeting/Proxy Form27/10/10
BLTCeasing to be a substantial holder22/10/10
BLTAppendix 3B Partial Conversion01/10/10
BLTBenitec Launches New Pain Therapeutic Program01/10/10
BLTFurther Update - Successful USPTO Board of Appeals DecisionPRICE SENSITIVE30/09/10
BLTUSPTO Board of Appeals reverses all 099 Graham rejectionsPRICE SENSITIVE30/09/10
BLTAppendix 3B Partial Conversion29/09/10
BLTSuccessful Grant of Further Hepatitis C RNAi Patent in USPRICE SENSITIVE29/09/10
BLTFull Year Statutory Accounts24/09/10
BLTAppendix 3B Partial Conversion20/09/10
BLTAppendix 3B Partial Conversion15/09/10
BLTPipeline and Strategy Update03/09/10
BLTAnother Patent in Graham Family Allowed in US02/09/10
BLTPreliminary Final ReportPRICE SENSITIVE31/08/10
BLTCleansing Notice20/08/10
BLTAppendix 3B Partial Conversion17/08/10
BLTResponse to ASX Query re Appendix 4CPRICE SENSITIVE11/08/10
BLT099 Graham Patent Re-examination Hearing at USPTO05/08/10
BLTCompany Contact Details29/07/10
BLTAppendix 3B Correction29/07/10
BLTAppendix 3B29/07/10
BLTAppendix 3B Partial Conversion28/07/10
BLTAppendix 4C - quarterlyPRICE SENSITIVE28/07/10
BLTContinues to Expand Patent Portfolio in Gene Expression14/07/10
BLTSecurities Update and Appendix 3B14/07/10
BLTRelease of Securities from Voluntary Escrow08/07/10
BLTResults of Meeting30/06/10
BLTBenitec granted Hepatitis C RNA Interference Patent in USPRICE SENSITIVE18/06/10
BLTBenitec HIV/AIDS Stem Cell Clinical Trial results publishedPRICE SENSITIVE17/06/10
BLTInitial results from Lung Cancer Collaboration published16/06/10
BLTCEO Principal Terms and Conditions of Employment15/06/10
BLTBenitec appoints DR Peter French as CEOPRICE SENSITIVE15/06/10
BLTAppendix 3B11/06/10
BLTInitial Director's Interest Notice02/06/10
BLTBenitec US Patent Re-exam Update02/06/10
BLTBenitec appoints Mr Iain Ross as Director01/06/10
BLTNotice of General Meeting/Proxy Form31/05/10
BLTAppendix 4C - quarterlyPRICE SENSITIVE29/04/10
BLTBenitec T cell HIV Trial Open for RecruitmentPRICE SENSITIVE12/04/10
BLTBenitec raises US$6 Million via Convertible NotePRICE SENSITIVE12/04/10
BLTFinal Director's Interest Notice31/03/10
BLTBenitec Board and Senior Management UpdatePRICE SENSITIVE29/03/10
BLTBenitec Graham Patent Granted in JapanPRICE SENSITIVE12/03/10
BLTBenitec US Patent Re-exam Update09/03/10
BLTChange in substantial holding05/03/10
BLTCompany Contact Details26/02/10
BLTHalf Yearly Report and AccountsPRICE SENSITIVE25/02/10
BLTAppendix 3B Issue of Shares25/02/10
BLTBenitec Licensee achieves Significant Milestone with PfizerPRICE SENSITIVE05/02/10
BLTInitial Director's Interest Notice03/02/10
BLTBenitec appoints Dr John Chiplin as Director01/02/10
BLTAppendix 4C Quarterly Cash Flow ReportPRICE SENSITIVE29/01/10
BLTCorrection: US Graham Patent 10/646,070 Notice of Allowance29/01/10
BLTUS Graham Patent 90/007,247 Notice of Allowance29/01/10
BLTBenitec US Re-exam UpdatePRICE SENSITIVE13/01/10
BLTAppendix 3B Issue of Shares11/01/10
BLTCompany Contact Details11/01/10
BLTTrading HaltPRICE SENSITIVE11/01/10
BLTBenitec and CSIRO reach Win-Win AgreementPRICE SENSITIVE04/01/10
BLTCEO Presentation to Shareholders18/11/09
BLTResults of Meeting18/11/09
BLTChairman's Address to AGM18/11/09
BLTAppendix 4C Quarterly Cash Flow ReportPRICE SENSITIVE30/10/09
BLTOptions Update23/10/09
BLTAdditional Information for AGM23/10/09
BLTNotice of Annual General Meeting/Proxy Form19/10/09
BLTAnnual Report to shareholders16/10/09
BLTNotice of Annual General Meeting/Proxy Form16/10/09
BLTMovements in Benitec Options15/10/09
BLTBenitec secures Rights to T cell HIV TherapeuticPRICE SENSITIVE06/10/09
BLTCollaboration on RNAi Therapeutic for Lung CancerPRICE SENSITIVE01/10/09
BLTBenitec Biomics Biotechnologies China Update07/09/09
BLTBenitec Fully Owned Patent Granted in USPRICE SENSITIVE31/08/09
BLTAppendix 4E and Full Year Annual ReportPRICE SENSITIVE28/08/09
BLTAppendix 3B correction04/08/09
BLTBenitec appoints new Chief Scientific Officer03/08/09
BLTFinal Issue of Shortfall Shares and Options31/07/09
BLTAppendix 3B Shortfall Allotment31/07/09
BLTCleansing Notice31/07/09
BLTAppendix 4C Quarterly Cash Flow ReportPRICE SENSITIVE30/07/09
BLTBenitec US Re-exam Update28/07/09
BLTBenitec MOU with Biomics Biotechnologies ChinaPRICE SENSITIVE14/07/09
BLTFurther Issue of Shortfall Shares and Options02/07/09
BLTAppendix 3B Shortfall Allotment02/07/09
BLTSection 708A Notice02/07/09
BLTExpiry of Unlisted Options29/06/09
BLTShare Trading Policy
14/12/10
BLTCorrection to Appendix 3B
13/12/10
BLTBenitec granted another RNA Interference Patent in Europe
13/12/10PRICE SENSITIVE
BLTAppendix 3B Exercise of Options
06/12/10
BLTAppendix 3B Partial Conversion
01/12/10
BLTResults of Meeting
29/11/10
BLTChairman Address To AGM
26/11/10
BLTBenitec Key Patent - Notice of Intent to Re-Issue in the USA
08/11/10PRICE SENSITIVE
BLTBenitec UK Patent Update
05/11/10PRICE SENSITIVE
BLTCleansing Notice
04/11/10
BLTBenitec Cash Flow Update
29/10/10
BLTAppendix 4C - quarterly
28/10/10PRICE SENSITIVE
BLTAppendix 3B Partial Conversion
27/10/10
BLTAnnual Report 2010
27/10/10
BLTNotice of Annual General Meeting/Proxy Form
27/10/10
BLTCeasing to be a substantial holder
22/10/10
BLTAppendix 3B Partial Conversion
01/10/10
BLTBenitec Launches New Pain Therapeutic Program
01/10/10
BLTFurther Update - Successful USPTO Board of Appeals Decision
30/09/10PRICE SENSITIVE
BLTUSPTO Board of Appeals reverses all 099 Graham rejections
30/09/10PRICE SENSITIVE
BLTAppendix 3B Partial Conversion
29/09/10
BLTSuccessful Grant of Further Hepatitis C RNAi Patent in US
29/09/10PRICE SENSITIVE
BLTFull Year Statutory Accounts
24/09/10
BLTAppendix 3B Partial Conversion
20/09/10
BLTAppendix 3B Partial Conversion
15/09/10
BLTPipeline and Strategy Update
03/09/10
BLTAnother Patent in Graham Family Allowed in US
02/09/10
BLTPreliminary Final Report
31/08/10PRICE SENSITIVE
BLTCleansing Notice
20/08/10
BLTAppendix 3B Partial Conversion
17/08/10
BLTResponse to ASX Query re Appendix 4C
11/08/10PRICE SENSITIVE
BLT099 Graham Patent Re-examination Hearing at USPTO
05/08/10
BLTCompany Contact Details
29/07/10
BLTAppendix 3B Correction
29/07/10
BLTAppendix 3B
29/07/10
BLTAppendix 3B Partial Conversion
28/07/10
BLTAppendix 4C - quarterly
28/07/10PRICE SENSITIVE
BLTContinues to Expand Patent Portfolio in Gene Expression
14/07/10
BLTSecurities Update and Appendix 3B
14/07/10
BLTRelease of Securities from Voluntary Escrow
08/07/10
BLTResults of Meeting
30/06/10
BLTBenitec granted Hepatitis C RNA Interference Patent in US
18/06/10PRICE SENSITIVE
BLTBenitec HIV/AIDS Stem Cell Clinical Trial results published
17/06/10PRICE SENSITIVE
BLTInitial results from Lung Cancer Collaboration published
16/06/10
BLTCEO Principal Terms and Conditions of Employment
15/06/10
BLTBenitec appoints DR Peter French as CEO
15/06/10PRICE SENSITIVE
BLTAppendix 3B
11/06/10
BLTInitial Director's Interest Notice
02/06/10
BLTBenitec US Patent Re-exam Update
02/06/10
BLTBenitec appoints Mr Iain Ross as Director
01/06/10
BLTNotice of General Meeting/Proxy Form
31/05/10
BLTAppendix 4C - quarterly
29/04/10PRICE SENSITIVE
BLTBenitec T cell HIV Trial Open for Recruitment
12/04/10PRICE SENSITIVE
BLTBenitec raises US$6 Million via Convertible Note
12/04/10PRICE SENSITIVE
BLTFinal Director's Interest Notice
31/03/10
BLTBenitec Board and Senior Management Update
29/03/10PRICE SENSITIVE
BLTBenitec Graham Patent Granted in Japan
12/03/10PRICE SENSITIVE
BLTBenitec US Patent Re-exam Update
09/03/10
BLTChange in substantial holding
05/03/10
BLTCompany Contact Details
26/02/10
BLTHalf Yearly Report and Accounts
25/02/10PRICE SENSITIVE
BLTAppendix 3B Issue of Shares
25/02/10
BLTBenitec Licensee achieves Significant Milestone with Pfizer
05/02/10PRICE SENSITIVE
BLTInitial Director's Interest Notice
03/02/10
BLTBenitec appoints Dr John Chiplin as Director
01/02/10
BLTAppendix 4C Quarterly Cash Flow Report
29/01/10PRICE SENSITIVE
BLTCorrection: US Graham Patent 10/646,070 Notice of Allowance
29/01/10
BLTUS Graham Patent 90/007,247 Notice of Allowance
29/01/10
BLTBenitec US Re-exam Update
13/01/10PRICE SENSITIVE
BLTAppendix 3B Issue of Shares
11/01/10
BLTCompany Contact Details
11/01/10
BLTTrading Halt
11/01/10PRICE SENSITIVE
BLTBenitec and CSIRO reach Win-Win Agreement
04/01/10PRICE SENSITIVE
BLTCEO Presentation to Shareholders
18/11/09
BLTResults of Meeting
18/11/09
BLTChairman's Address to AGM
18/11/09
BLTAppendix 4C Quarterly Cash Flow Report
30/10/09PRICE SENSITIVE
BLTOptions Update
23/10/09
BLTAdditional Information for AGM
23/10/09
BLTNotice of Annual General Meeting/Proxy Form
19/10/09
BLTAnnual Report to shareholders
16/10/09
BLTNotice of Annual General Meeting/Proxy Form
16/10/09
BLTMovements in Benitec Options
15/10/09
BLTBenitec secures Rights to T cell HIV Therapeutic
06/10/09PRICE SENSITIVE
BLTCollaboration on RNAi Therapeutic for Lung Cancer
01/10/09PRICE SENSITIVE
BLTBenitec Biomics Biotechnologies China Update
07/09/09
BLTBenitec Fully Owned Patent Granted in US
31/08/09PRICE SENSITIVE
BLTAppendix 4E and Full Year Annual Report
28/08/09PRICE SENSITIVE
BLTAppendix 3B correction
04/08/09
BLTBenitec appoints new Chief Scientific Officer
03/08/09
BLTFinal Issue of Shortfall Shares and Options
31/07/09
BLTAppendix 3B Shortfall Allotment
31/07/09
BLTCleansing Notice
31/07/09
BLTAppendix 4C Quarterly Cash Flow Report
30/07/09PRICE SENSITIVE
BLTBenitec US Re-exam Update
28/07/09
BLTBenitec MOU with Biomics Biotechnologies China
14/07/09PRICE SENSITIVE
BLTFurther Issue of Shortfall Shares and Options
02/07/09
BLTAppendix 3B Shortfall Allotment
02/07/09
BLTSection 708A Notice
02/07/09
BLTExpiry of Unlisted Options
29/06/09
refresh Created with Sketch. REFRESH
 

Top Stories

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

Pan Asia Metals has scored $35 million from a New York private equity firm at the same time as the company's big rebrand push begins.
This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game Today, one small pill holds the potential to transform cognitive medicine by addressing conditions like depression and Alzheimer’s. 
MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up Who the MinRes Board has decided to move on faster may or may not be amusing, depending on how much you've lost.
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025 Samples among the highest-ever-graded uranium soil samples recorded in mineral exploration history, and an imminent drill run.
Week 48 Wrap: ASX flirts with 8,500pts; APRA declines mortgage loan easing; Trump's Bessent tied to Dem donor The ASX200 has been really flirting with the 8,500pts mark this week, notching an intraweek ATH of 8,476pts.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.